Protocol Ledger

NCT03712202 · Phase II · ACTIVE NOT RECRUITING

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Interventional Phase II clinical trial protocol NCT03712202 sponsored by City of Hope in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-28 Enrollment: 159 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03712202
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)159 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03712202
Protocol FieldVerified Registry Value
NCT IdentifierNCT03712202
Consolidated Lead SponsorCity of Hope
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment159 participants (ACTUAL)
Registered Start Date2018-11-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for City of Hope across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI